The provided text consists of excerpts from a Merck & Co., Inc. Third-Quarter 2025 Sales and Earnings conference call presentation, outlining the company's performance, strategy, and pipeline updates. The presentation highlights $17.3 billion in worldwide sales for the quarter, driven by strong growth in Oncology, particularly KEYTRUDA ($8.1 billion in sales), and Animal Health. Management discusses the company's focus on innovation and growth, citing a pipeline with around 80 Phase 3 trials and a strategic acquisition, Verona Pharma, for a new COPD treatment. The report also details progress across various therapeutic areas, including Immunology, Ophthalmology, and Cardiopulmonary diseases, along with an updated 2025 financial outlook predicting non-GAAP EPS between $8.93 and $8.98.